• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型苯硝唑固体分散体的制备、溶解特性及作为替代抗查加斯病药物传递系统的生物学评价。

Novel solid dispersions of benznidazole: preparation, dissolution profile and biological evaluation as alternative antichagasic drug delivery system.

机构信息

CEI Campus Moncloa, UCM-UPM & CSIC, Madrid, Spain; Departamento de Parasitología, Facultad de Farmacia, Universidad Complutense de Madrid, Pza. Ramón y Cajal s/n, Madrid 28040, Spain.

Departamento de Farmacia y Tecnología Farmacéutica, Facultad de Farmacia, Universidad Complutense de Madrid, Pza. Ramón y Cajal s/n, Madrid 28040, Spain.

出版信息

Exp Parasitol. 2015 Feb;149:84-91. doi: 10.1016/j.exppara.2015.01.002. Epub 2015 Jan 9.

DOI:10.1016/j.exppara.2015.01.002
PMID:25583295
Abstract

Solid dispersions (SD) of benznidazole (BNZ) in sodium deoxycholate (NaDC) or low-substituted hydroxypropylcellulose (L-HPC) were developed by freeze-drying process to improve the solubility of this low water-soluble drug and consequently, its trypanocidal activity. Although the dissolution studies showed a progressive decrease in the release rate of BNZ when formulated in the presence of NaDC, the increase in the surfactant concentration resulted in a better trypanocidal profile on epimastigotes, as well as in an enhancement of the unspecific cytotoxicity. However, such an effect was not so evident on amastigotes and in vivo (blood-trypomastigotes), where high concentrations of surfactant (BNZ:NaDC ≥ 1:6) experimented a loss of activity, correlating this fact with the minor cession of BNZ these formulations accomplished in acidic locations (i.e., dissolution test medium). According to the in vitro results, we reformulated the promising SD-1:3 (IC₅₀ epimastigotes = 33.92 ± 6.41 µM, IC₅₀ amastigotes = 0.40 ± 0.05 µM and LC₅₀ = 183.87 ± 12.30 µM) replacing NaDC by L-HPC, which achieved the fastest dissolution profile. This fact, together with the safety this carrier ensures (LC₅₀ > 256 µM), prompted us to evaluate the cellulose SD in vivo, improving the effectiveness of its NaDC equivalent (%AUPC = 96.65% and 91.93%, respectively). The results compiled in the present work suggest these solid dispersions as alternative drug delivery systems to improve the limited chemotherapy of Chagas disease.

摘要

采用冷冻干燥法制备了苯硝唑(BNZ)在脱氧胆酸钠(NaDC)或低取代羟丙基纤维素(L-HPC)中的固体分散体,以提高这种低水溶性药物的溶解度,从而提高其杀锥虫活性。虽然溶解研究表明,当用 NaDC 配制时,BNZ 的释放率逐渐降低,但表面活性剂浓度的增加导致对前鞭毛体的杀锥虫谱更好,以及非特异性细胞毒性增强。然而,这种效应在无鞭毛体和体内(血液-锥鞭毛体)中并不那么明显,在这些部位,高浓度的表面活性剂(BNZ:NaDC ≥ 1:6)会失去活性,这与这些制剂在酸性部位(即溶解试验介质)中 BNZ 的含量减少有关。根据体外结果,我们用 L-HPC 替代有前途的 SD-1:3(IC₅₀ 前鞭毛体= 33.92 ± 6.41 μM,IC₅₀ 无鞭毛体= 0.40 ± 0.05 μM 和 LC₅₀ = 183.87 ± 12.30 μM)重新配制了 SD-1:3,从而实现了最快的溶解曲线。这一事实,再加上这种载体所保证的安全性(LC₅₀ > 256 μM),促使我们在体内评估纤维素 SD,提高其 NaDC 等效物的有效性(%AUPC = 96.65%和 91.93%)。本工作中总结的结果表明,这些固体分散体可以作为改善恰加斯病有限化疗的替代药物传递系统。

相似文献

1
Novel solid dispersions of benznidazole: preparation, dissolution profile and biological evaluation as alternative antichagasic drug delivery system.新型苯硝唑固体分散体的制备、溶解特性及作为替代抗查加斯病药物传递系统的生物学评价。
Exp Parasitol. 2015 Feb;149:84-91. doi: 10.1016/j.exppara.2015.01.002. Epub 2015 Jan 9.
2
Development of novel benznidazole formulations: physicochemical characterization and in vivo evaluation on parasitemia reduction in Chagas disease.新型苯硝唑制剂的研发:恰加斯病寄生虫血症降低方面的物理化学特性及体内评价
Int J Pharm. 2014 Sep 10;472(1-2):110-7. doi: 10.1016/j.ijpharm.2014.06.015. Epub 2014 Jun 10.
3
Enhanced delivery of fixed-dose combination of synergistic antichagasic agents posaconazole-benznidazole based on amorphous solid dispersions.基于无定形固体分散体的协同抗恰加斯病药物泊沙康唑-苯硝唑固定剂量组合的增强递送。
Eur J Pharm Sci. 2018 Jul 1;119:208-218. doi: 10.1016/j.ejps.2018.04.024. Epub 2018 Apr 19.
4
Technological innovation strategies for the specific treatment of Chagas disease based on Benznidazole.基于苯硝唑的恰加斯病特异性治疗技术创新策略。
Acta Trop. 2018 Sep;185:127-132. doi: 10.1016/j.actatropica.2018.02.008. Epub 2018 Feb 13.
5
Tailoring microstructural, drug release properties, and antichagasic efficacy of biocompatible oil-in-water benznidazol-loaded nanoemulsions.定制载苯并硝唑的生物相容性油包水型纳米乳的微观结构、药物释放特性和抗恰加斯病疗效。
Int J Pharm. 2019 Jan 30;555:36-48. doi: 10.1016/j.ijpharm.2018.11.041. Epub 2018 Nov 15.
6
Benznidazole microcrystal preparation by solvent change precipitation and in vivo evaluation in the treatment of Chagas disease.溶剂变化沉淀法制备苯并硝唑微晶体及其在治疗恰加斯病中的体内评价。
Eur J Pharm Biopharm. 2011 Aug;78(3):377-84. doi: 10.1016/j.ejpb.2011.03.003. Epub 2011 Mar 17.
7
Preparation and Characterization of Poloxamer 407 Solid Dispersions as an Alternative Strategy to Improve Benznidazole Bioperformance.制备和表征泊洛沙姆 407 固体分散体作为改善苯并咪唑生物性能的替代策略。
J Pharm Sci. 2018 Nov;107(11):2829-2836. doi: 10.1016/j.xphs.2018.06.027. Epub 2018 Jul 10.
8
Organic solvent-free benznidazole nanosuspension as an approach to a novel pediatric formulation for Chagas disease.无有机溶剂苯硝唑纳米混悬液作为一种新型儿科锥虫病制剂的方法。
Ther Deliv. 2024;15(9):699-716. doi: 10.1080/20415990.2024.2380244. Epub 2024 Aug 5.
9
Benznidazole in vitro dissolution release from a pH-sensitive drug delivery system using Zif-8 as a carrier.使用 Zif-8 作为载体的 pH 敏感药物传递系统中苯并咪唑的体外溶出释放。
J Mater Sci Mater Med. 2021 May 17;32(6):59. doi: 10.1007/s10856-021-06530-w.
10
Selective activity of 2,4-diaryl-1,2,3,4-tetrahydroquinolines on Trypanosoma cruzi epimastigotes and amastigotes expressing β-galactosidase.2,4-二芳基-1,2,3,4-四氢喹啉类化合物对表达β-半乳糖苷酶的克氏锥虫滋养体和无鞭毛体的选择性作用。
Bioorg Med Chem Lett. 2013 Sep 1;23(17):4851-6. doi: 10.1016/j.bmcl.2013.06.079. Epub 2013 Jul 12.

引用本文的文献

1
Organic solvent-free benznidazole nanosuspension as an approach to a novel pediatric formulation for Chagas disease.无有机溶剂苯硝唑纳米混悬液作为一种新型儿科锥虫病制剂的方法。
Ther Deliv. 2024;15(9):699-716. doi: 10.1080/20415990.2024.2380244. Epub 2024 Aug 5.
2
Poly-ε-Caprolactone Implants for Benznidazole Prolonged Release: An Alternative to Chagas Disease Oral Treatment.用于苯硝唑缓释的聚ε-己内酯植入物:恰加斯病口服治疗的替代方法。
Pharmaceutics. 2023 Apr 2;15(4):1126. doi: 10.3390/pharmaceutics15041126.
3
Current Trends on Solid Dispersions: Past, Present, and Future.
固体分散体的当前趋势:过去、现在和未来
Adv Pharmacol Pharm Sci. 2022 Oct 22;2022:5916013. doi: 10.1155/2022/5916013. eCollection 2022.
4
Therapeutic Applications of Solid Dispersions for Drugs and New Molecules: In Vitro and In Vivo Activities.固体分散体在药物及新分子中的治疗应用:体外和体内活性
Pharmaceutics. 2020 Sep 30;12(10):933. doi: 10.3390/pharmaceutics12100933.
5
Using prodigiosin against some gram-positive and gram-negative bacteria and .使用灵菌红素对抗某些革兰氏阳性菌和革兰氏阴性菌以及…… (原文句子不完整)
J Venom Anim Toxins Incl Trop Dis. 2019 Jun 3;25:e20190001. doi: 10.1590/1678-9199-JVATITD-2019-0001. eCollection 2019.
6
Benznidazole Nanoformulates: A Chance to Improve Therapeutics for Chagas Disease.苯硝唑纳米制剂:改善恰加斯病治疗方法的契机。
Am J Trop Med Hyg. 2017 Nov;97(5):1469-1476. doi: 10.4269/ajtmh.17-0044. Epub 2017 Oct 10.
7
Characterization of Heterogeneity and Spatial Distribution of Phases in Complex Solid Dispersions by Thermal Analysis by Structural Characterization and X-ray Micro Computed Tomography.通过结构表征和X射线显微计算机断层扫描热分析对复杂固体分散体中相的异质性和空间分布进行表征
Pharm Res. 2017 May;34(5):971-989. doi: 10.1007/s11095-016-1923-3. Epub 2016 Apr 19.